Scientists who want a say in the future of their inventions are once again moving from academia to the C-suite ...

Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 ...

Norwegian clinical-stage biotech Nykode Therapeutics revealed that it has received notification from Genentech, a US ...

Nykode Therapeutics (VACBF) announced last night that it has received notification from Genentech, a member of the Roche (RHHBY), of its ...

As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being portrayed in the presidential ...

The United States is home to one of the leading healthcare systems globally, primarily due to its remarkable ability to drive ...

--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline ...

Roche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its repertoire. The three drug discovery deals are with Convelo Therapeutics in neurological ...

“Onco360 is grateful for the opportunity to partner with the team at Genentech and become a specialty pharmacy provider for Itovebi ™ ,” said Benito Fernandez. “We are proud to add another treatment ...

Upfront License Fees and Milestone Payments: Received $50 million from Genentech. Cash Runway: Sufficient to fund operations ...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported business highlights and third quarter 2024 financial results. "This is ...